Health Technology · Pharmaceuticals: Major · NSE: KILITCH · data 2026-10-09
Kilitch Drugs (India) Limited
Health check: Strong (7.9/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹241.61
Market cap
₹852 cr
P/E
27.7
P/B
—
ROE
12.5%
ROCE
12.3%
Debt / equity
0.32
Dividend yield
0.00%
1-year return
37.1%
52-week high
₹267.9
52-week low
₹117.25
Operating margin
13.7%
Growth
| Revenue (last 12 months) | ₹237 cr |
| Net profit (last 12 months) | ₹30 cr |
| Sales growth, 3 years (yearly) | 19.0% |
| Profit growth, 3 years (yearly) | 42.4% |
Chart patterns
- Double bottom — breakout (key level ₹199.59)
Similar companies
Bafna Pharmaceuticals Limited (BAFNAPH) · Shree Ganesh Remedies Ltd. (SGRL) · Hexagon Nutrition Limited (HEXAGON) · Anuh Pharma Limited (ANUHPHR) · Amanta Healthcare Limited (AMANTA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KILITCH in NSE Scanner →